Atellica DCA Analyzer

Diabetes testing, evolved

siemens-healthineers.com/poc
What if you could diagnose diabetes early and regularly monitor your patients?

More than 463 million people around the world have diabetes¹

Diabetes is one of the largest global-health emergencies of the 21st century. It continues to grow in prevalence but remains largely undetected.

By 2045 it’s projected that 700 million people will have diabetes.¹

50% don’t know it.¹

A 1% reduction in HbA1c may reduce amputation or death caused by blocked blood vessels by 43% and reduce instance of heart attack by 14%.²

Studies show that HbA1c levels reduce faster with point-of-care (POC) testing.³

A 1% reduction in HbA1c may reduce amputation or death caused by blocked blood vessels by 43% and reduce instance of heart attack by 14%.²

Studies show that HbA1c levels reduce faster with point-of-care (POC) testing.³
Routine POC diabetes testing can improve patient outcomes and help meet KPIs

Siemens Healthineers solutions help providers achieve better results for clinics and patients.

**High patient-satisfaction scores: 3.96 out of 4.0**
Studies demonstrated flexible and improved patient workflows, which led to productive patient dialogue.
Improving care plans led to high patient-satisfaction scores: 3.96 out of 4.0.4,5

**Help improve patient glycemic control and identify early kidney disease**
Studies have shown an overall reduction in A1c levels by as much as 35% for patients monitored with POC HbA1c testing vs. the lab.3,5
POC albumin:creatinine ratio (ACR) testing identified 45% of patients with abnormal levels who needed immediate follow-up care.6

**Proven to have a positive financial impact of $24.65 per patient**
In a study using POC HbA1c analyzers, testing was shown to lower operational costs by optimizing clinical operations and thereby reducing follow-up phone calls/letters and patient revisits.4

**Help increase rate of early diagnoses**
The use of a POC HbA1c test vs. standard practices greatly increases the likelihood of screening adults for diabetes.7

<table>
<thead>
<tr>
<th>Identify chronic hyperglycemia</th>
<th>Identify prediabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>POCCT</td>
<td>Standard practices</td>
</tr>
<tr>
<td>63%</td>
<td>53%</td>
</tr>
<tr>
<td>41%</td>
<td>33%</td>
</tr>
</tbody>
</table>

improve PATIENT EXPERIENCE
increase EFFECTIVENESS OF CARE
improve OPERATING MARGIN
increase RATE OF DIAGNOSES
Atellica DCA Analyzer

Building upon one of the industry’s most trusted technologies for diabetes testing, the Atellica® DCA Analyzer puts fast, quality results right at your fingertips. Experience the performance and precision you need to improve outcomes, and get the speed, standardization, and personalization you want to boost efficiencies and meet growing demand.
Freedom to optimize your workflows and evolve your POC experience

Scalable and connected
Connect and operate up to three test modules with a single display and transmit results with secure BLUETOOTH, wireless, or wired connections for seamless data transmission to LIS/HIS/EHR systems.

Flexible workflow
Link patient IDs and access results from wherever they are needed.

Compact and portable
The system’s small footprint, light weight, and built-in handle enable easy movement for storage or bringing directly to patient.

Three easy steps
Insert cartridge.
Pull buffer tab.
Close door.
Results available in only 4 minutes!
**Gain confidence with results you can trust**

**Trusted performance**
- Lab-quality results using technology with 30+ years of proven clinical reliability.
- Atellica DCA Analyzer strongly correlated to results from the Tosoh G8 laboratory method.\(^8\)

**Built-in safeguards**
- Auto-Checks\(^\circ\) technology ensures accurate sample processing and reliable results, and built-in risk mitigation features provide an audit-ready solution.
- Liquid ready controls help prevent pre-analytical errors.
- Security measures protect patient data.
  - No patient data transmitted between display and module.
  - Operator access control prevents unauthorized access.
  - Operator lockout after five failed attempts.
  - TLS encryption protects from cybersecurity threats.
  - USB debugging port is disabled.
  - Manually exported data is password-protected.

**Intuitive user interface**
Simple operation and an intuitive UI decrease the likelihood of operator error, improve user experience, and reduce training complexity.

---

\(^{8}\) Atellica DCA Analyzer strongly correlated to results from the Tosoh G8 laboratory method.

\(^{9}\) No clinically significant interferences from common hemoglobin variants for HbA1c measurements.
When we started, the hospital admission rate was between 20% and 30%. Now most clinics can get to around 10%, while we have rates of between 1% and 3%. That’s a real benefit for patients and a big cost saver.

Dr. Henk Veese
Pediatric Diabetologist and Co-founder
Diabetes Treatment Program, Rotterdam, Netherlands

POCT can significantly improve clinical operations with cost reductions through improved practice efficiency. The economic benefits of POCT may be realized in both fee-for-service and global payment environments.

J. Benjamin Crocker, MD
Medical Director, Ambulatory Practice of the Future
Massachusetts General Hospital, Boston, MA

A legacy of innovation and impact

30 yrs
of trusted immunoassay technology

600+
peer-reviewed articles and clinical citations

NGSP- and IFCC-certified annually
At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

Atellica, Auto-Checks, DCA, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

References:
7. www.annfammed.org/content/15/2/162.full.pdf.
8. Siemens Healthcare Diagnostics Inc. Internal study conducted at Western Michigan University School of Medicine. 2019.